COVID-19 assay development and reagents

nanoComposix Partners with CliniSciences to Broaden Distribution of Products to Customers Throughout Europe

February 28, 2019

San Diego, California – nanoComposix has signed an agreement with CliniSciences (www.clinisciences.com), establishing a partnership toward expanding the distribution of nanoComposix materials and technologies to customers throughout Europe.

nanoComposix (www.nanocomposix.com) has been providing customers with precisely engineered and highly characterized nanoparticles for the last 15 years, offering hundreds of different variants of material, size, shape, and surface functionalization as stock products. In addition, the company produces custom nanomaterials, from core/shell particles to biofunctionalized, fluorescent, and magnetic nanocomposites to meet individual client specifications. Each material is provided with a certificate of analysis that includes a full suite of characterization services including optical data, electron microscopy analysis, hydrodynamic diameter, and pH readings to verify that every sample satisfies the company’s product specifications. nanoComposix executes contract manufacturing on scales ranging from small beakers to thousands of liters. Nanomaterials for medical devices and clinical trials are fabricated in ISO13485 and cGMP compliant cleanroom facilities.

CliniSciences is a European distributor of Life Science reagents and instruments for immunology, cell biology, and molecular biology. Other research areas they support include stem cells, cell & plant biology, apoptosis, neuroscience, metabolism, and protein studies. The company is based in France and has distribution subsidiaries in many countries across Europe, each with local representatives in the field to provide customers with resources and services to support them through the various stages of diagnostic development and fundamental research. In addition to distributing products from a wide range of vendors around the world, CliniSciences offers consultation and a suite of custom services, ranging from custom gene targeting in cell lines to in vivo infectious disease modeling and ultrasensitive biomarker testing.

The nanoComposix product offerings fit in well with the range of products and services supported at CliniSciences. The two companies are enthusiastic to see what new opportunities result from this partnership.

nanoComposix can be visited online at: www.nanocomposix.com

CliniSciences can be visited online at: www.clinisciences.com